What is HC Wainwright’s Estimate for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Neurogene in a research note issued on Tuesday, March 25th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($0.85) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.98) EPS and FY2025 earnings at ($3.68) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter.

Separately, William Blair restated an “outperform” rating on shares of Neurogene in a report on Tuesday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $59.80.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $15.33 on Thursday. The firm’s 50 day moving average price is $16.92 and its 200-day moving average price is $28.96. Neurogene has a 52-week low of $13.47 and a 52-week high of $74.49. The company has a market cap of $227.73 million, a PE ratio of -3.59 and a beta of 1.01.

Institutional Trading of Neurogene

Large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in Neurogene by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock valued at $1,272,000 after acquiring an additional 741 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock valued at $73,000 after purchasing an additional 989 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Neurogene by 9.2% in the 4th quarter. Rhumbline Advisers now owns 15,704 shares of the company’s stock worth $359,000 after purchasing an additional 1,326 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Neurogene by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after buying an additional 1,397 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Neurogene by 192.8% during the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after buying an additional 1,429 shares during the period. Institutional investors own 52.37% of the company’s stock.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the transaction, the chief financial officer now directly owns 72,343 shares of the company’s stock, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 9.92% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.